全文获取类型
收费全文 | 181篇 |
免费 | 11篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 24篇 |
妇产科学 | 2篇 |
基础医学 | 16篇 |
口腔科学 | 7篇 |
临床医学 | 24篇 |
内科学 | 28篇 |
皮肤病学 | 6篇 |
神经病学 | 12篇 |
特种医学 | 31篇 |
外科学 | 11篇 |
综合类 | 14篇 |
预防医学 | 12篇 |
眼科学 | 1篇 |
药学 | 7篇 |
中国医学 | 1篇 |
肿瘤学 | 2篇 |
出版年
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 6篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 5篇 |
2015年 | 6篇 |
2014年 | 3篇 |
2013年 | 2篇 |
2012年 | 1篇 |
2011年 | 2篇 |
2010年 | 11篇 |
2009年 | 5篇 |
2008年 | 5篇 |
2007年 | 3篇 |
2006年 | 4篇 |
2005年 | 4篇 |
2004年 | 6篇 |
2003年 | 4篇 |
2001年 | 8篇 |
2000年 | 3篇 |
1999年 | 5篇 |
1998年 | 10篇 |
1997年 | 9篇 |
1996年 | 15篇 |
1995年 | 10篇 |
1994年 | 12篇 |
1993年 | 7篇 |
1992年 | 4篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1988年 | 1篇 |
1987年 | 8篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 4篇 |
1979年 | 1篇 |
1976年 | 2篇 |
排序方式: 共有198条查询结果,搜索用时 15 毫秒
1.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
2.
3.
4.
5.
6.
The aim was to evaluate neuropsychological performance and its pre-, and perinatal predictors in low birth weight (LBW) preschool
children. A population-based sample of 137 5-year-old children with birth weights less than 2000 g and without major handicaps
was compared with a random sample of 152 normal birth weight term controls. Main assessment tools were all subscales from
the Wechsler Preschool and Primary Scale of Intelligence Revised, subscales from the Illinois Test of Psycholinguistic Abilities
and tests of manual dexterity and figure copying. The LBW children showed significantly lower mean scores compared to controls
on tests of visuo-spatial and visuo-motor abilities, but were comparable to controls in other areas, confounding parental
factors were controlled for. 14 of the LBW children, there were signs of maternal chorio-amnionitis. Twelve of these had premature
rupture of membranes lasting more than 24 h. These 14 children had a mean performance IQ of 87 (SD 5) compared to 100 (SD
15) for the LBW children without maternal signs of chorio-amnionitis (P = 0.001). Having a small head circumference at birth was a less powerful, but statistically significant predictor of impaired
performance.
Conclusion Low birth weight is associated with impaired performance on visuo-spatial and visuo-motor tasks. Signs of maternal chorio-amnionitis
and a small head circumference at birth may be risk factors for such impairment.
Received: 20 November 1996 / Accepted: 5 May 1997 相似文献
7.
Warkentin TE; Hayward CP; Boshkov LK; Santos AV; Sheppard JA; Bode AP; Kelton JG 《Blood》1994,84(11):3691-3699
Heparin-induced thrombocytopenia is characterized by moderate thrombocytopenia and thrombotic complications, whereas quinine/quinidine-induced thrombocytopenia usually presents with severe thrombocytopenia and bleeding. Using flow cytometry and assays of procoagulant activity, we investigated whether sera from patients with these immune drug reactions could stimulate normal platelets to generate platelet-derived microparticles with procoagulant activity. Sera or purified IgG from patients with heparin-induced thrombocytopenia stimulated the formation of platelet-derived microparticles in a heparin-dependent fashion. Further studies showed that heparin-induced thrombocytopenia sera also produced a marked increase in procoagulant activity. In contrast, sera from patients with quinine- or quinidine-induced thrombocytopenia did not generate platelet-derived microparticles nor generate increased procoagulant activity. However, quinine/quinidine-induced thrombocytopenia sera produced a significant increase in the binding of IgG to platelets in a drug-dependent fashion, whereas sera from patients with heparin-induced thrombocytopenia demonstrated no drug-dependent binding of IgG to platelets. We also observed increased levels of circulating microparticles in patients with acute heparin-induced thrombocytopenia compared with control patients. Our observations indicate that the generation of procoagulant platelet-derived microparticles in vivo is a plausible explanation for the thrombotic complications observed in some patients with heparin-induced thrombocytopenia. 相似文献
8.
9.
Nittaya Phanuphak Nipat Teeratakulpisarn Frits van Griensven Nitiya Chomchey Suteeraporn Pinyakorn James LK Fletcher Rapee Trichavaroj Supanit Pattanachaiwit Nelson Michael Praphan Phanuphak Jerome H Kim Jintanat Ananworanich 《Journal of the International AIDS Society》2015,18(1)
Introduction
HIV transmission risk is highest during acute HIV infection (AHI). We evaluated HIV RNA in the anogenital compartment in men who have sex with men (MSM) during AHI and compared time to undetectable HIV RNA after three-drug versus five-drug antiretroviral therapy (ART) to understand risk for onward HIV transmission.Methods
MSM with AHI (n=54) had blood, seminal plasma and anal lavage collected for HIV RNA at baseline, days 3 and 7, and weeks 2, 4, 12 and 24. Data were compared between AHI stages: 1 (fourth-generation antigen-antibody combo immunoassay [IA]–, third-generation IA–, n=15), 2 (fourth-generation IA+, third-generation IA–, n=9) and 3 (fourth-generation IA+, third-generation IA+, western blot–/indeterminate, n=30) by randomization to five-drug (tenofovir+emtricitabine+efavirenz+raltegravir+maraviroc, n=18) versus three-drug (tenofovir+emtricitabine+efavirenz, n=18) regimens.Results
Mean age was 29 years and mean duration since HIV exposure was 15.4 days. Mean baseline HIV RNA was 5.5 in blood, 3.9 in seminal plasma and 2.6 log10 copies/ml in anal lavage (p<0.001). Blood and seminal plasma HIV RNA were higher in AHI Stage 3 compared to Stage 1 (p<0.01). Median time from ART initiation to HIV RNA <50 copies/ml was 60 days in blood, 15 days in seminal plasma and three days in anal lavage. Compared with the three-drug ART, the five-drug ART had a shorter time to HIV RNA <1500 copies/ml in blood (15 vs. 29 days, p=0.005) and <50 copies/ml in seminal plasma (13 vs. 24 days, p=0.048).Conclusions
Among MSM with AHI, HIV RNA was highest in blood, followed by seminal plasma and anal lavage. ART rapidly reduced HIV RNA in all compartments, with regimen intensified by raltegravir and maraviroc showing faster HIV RNA reductions in blood and seminal plasma. 相似文献10.